EFEMP2
EFEMP2, also known as EGF-containing fibulin-like extracellular matrix protein 2, is a protein that in humans is encoded by the EFEMP2 gene. This protein is a member of the fibulin family, a group of extracellular matrix (ECM) proteins that play a crucial role in connective tissue organization and various cellular processes. EFEMP2 is involved in the structural organization of the ECM and has been implicated in a range of biological functions, including cell adhesion, migration, and the regulation of angiogenesis.
Function[edit | edit source]
EFEMP2 is an important component of the extracellular matrix, contributing to its formation and maintenance. It interacts with other ECM proteins such as fibronectin, elastin, and collagen, facilitating the assembly of the ECM and influencing cellular behaviors critical for tissue repair and development. The protein is also involved in the modulation of angiogenesis, the process through which new blood vessels form, which is essential for wound healing and the growth of tissues and organs.
Genetic and Clinical Aspects[edit | edit source]
Mutations in the EFEMP2 gene are associated with a rare genetic disorder known as autosomal dominant Cutis laxa, specifically type 2 (also referred to as ADCL2). This condition is characterized by a marked laxity of the skin, leading to premature aging, and in some cases, the development of systemic complications affecting the lungs, arteries, and gastrointestinal system. The mutations lead to abnormal synthesis or structure of the EFEMP2 protein, disrupting the integrity and function of the extracellular matrix.
Research and Potential Therapeutic Targets[edit | edit source]
Research into EFEMP2 has also highlighted its potential role in the pathogenesis of certain cancers and fibrotic diseases. Its involvement in angiogenesis and ECM remodeling makes it a candidate for therapeutic targeting in diseases where these processes are dysregulated. However, further research is needed to fully understand its mechanisms of action and to develop effective strategies for targeting EFEMP2 in clinical settings.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
